ClinicalTrials.gg
CompletedNCT06653556Updated Oct 14, 2026

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

An Early Phase 1 interventional study of LCAR-AIO T cells in Systemic Lupus Erythematosus (SLE), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Enrollment
10th of 11
3 · median 12
Started
2025
with 2 others
Phase 1
7 of 11
5 open now
Registered
4th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 10th largest by enrollment, is one of 3 that started in 2025, is one of 7 in phase 1, and was the 4th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, or all of them as a file.
02

Study summary

This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.

Read the detailed description

This is a prospective, single-arm, open-label exploratory clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy profiles of LCAR-AIO, a chimeric antigen receptor (CAR) -T cell therapy in subjects with relapsed/refractory systemic lupus erythematosus. Patients who meet the eligibility criteria will receive LCAR-AIO infusion. The study will include the following sequential stages: screening, apheresis, pre-treatment (cell product preparation: lymphodepleting chemotherapy), treatment (LCAR AIO infusion) and follow-up.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Refractory pulmonary Hypertension (PAH)
  • Recurrent/refractory autoimmune hemolytic anemia (r/r AIHA)
  • Recurrent/refractory lupus nephritis (r/r LN)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Subjects voluntarily participate in clinical research.
  2. Age 18-65 years.
  3. Have been diagnosed of SLE at least 6 months before screening.
  4. At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Sm antibody should be positive.
  5. Fulfill SLE conditions.
  6. Adequate organ function at screening.
  7. Clinical laboratory values meet criteria at screening.

Exclusion Criteria:

  1. Active infections such as hepatitis and tuberculosis.
  2. Other diseases.
  3. Serious underlying diseases such as tumor, uncontrolled diabetes.
  4. Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving LCAR-AIO treatment.
  5. Participated in other clinical trials within
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    LCAR-AIO T Cells

    Experimental: Chimeric antigen receptor T cells (LCAR-AIO) Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level

    Biological: LCAR-AIO T cells

Interventions

  • BiologicalLCAR-AIO T cells

    Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and type of treatment-emergent adverse events (TEAEs)

    An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

  2. Incidence of dose-limiting toxicity (DLT)

    DLTs are severe adverse events refers to any untoward medical occurred in a subject participated in a clinical investigation, which have a causal relationship with the treatment and will limit the dose escalation.

    Time frame: 30 days after LCAR-AIO infusion (Day 1)

  3. Pharmacokinetics in peripheral blood

    CAR positive T cells levels in peripheral blood after LCAR-AIO infusion.

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

  4. Recommended Phase 2 Dose (RP2D) regimen finding

    RP2D established through dose exploratory.

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

Secondary outcomes

  1. Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores from baseline up to 104 weeks

    The SELENA-2K scale is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-2K total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

  2. Change in Physician global assessment (PGA) scores from baseline up to 104 weeks

    The physician will place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (Score 0) represents "no activity", and the right-hand boundary (score 3) represents "the most severe activity".

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

  3. Lupus Low Disease Activity State (LLDAS) response rates at multiple visits post-infusion

    Percentage of participants achieving the LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (Central nervous system, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) Physician global assessment (PGA) (score 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg dailyultiple visits.

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

  4. 24h urinary protein/urine protein-to-creatinine ratio (UPCR) changes from baseline up to 104 weeks

    Proteinuria will be assessed in lupus nephritis patients basing on 24h urinary protein/UPCR at multiple visits.

    Time frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

  5. Changes from baseline in immunological markers and Immunogenicity (anti-drug antibody)

    Detection of Immunoglobulins, anti-drug antibodies (anti-dsDNA antibody, anti-Sm antibody, etc.) and anti-drug antibody.

    Time frame: Time Frame: Minimum 104 Weeks after LCAR-AIO infusion (Day 1)

07

Study locations

1 site
  • Wuhan Union Hospital
    Wuhan, Hubei, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2026, 16 months.

Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 16 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2027 → Jun 2026 and completion Sep 2029 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 22, 2024
StartActual
Jan 8, 2025
Primary completionActual
Jun 6, 2026was Sep 2027
CompletionActual
Jun 6, 2026was Sep 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 14, 2026
Primary completion
Sep 30, 2027→Jun 6, 2026 (actual)
Oct 14, 2026
Study completion
Sep 30, 2029→Jun 6, 2026 (actual)
Oct 14, 2026
Enrollment
34 (estimated)→3 (actual)
Oct 14, 2026
Sponsor
Wuhan Union Hospital, China→Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2027→Jun 6, 2026 (now actual)
    Study completion Sep 30, 2029→Jun 6, 2026 (now actual)
    Enrollment 34 (estimated)→3 (actual)
    Sponsor Wuhan Union Hospital, China→Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    + 5 other changes: index terms, identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06653556
Collaborators
Nanjing Legend Biotech Co., Beijing GoBroad Hospital
Responsible party
Qiubai Li (Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Oct 22, 2024
Start date
Jan 8, 2025
Primary completion
Jun 6, 2026
Completion
Jun 6, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion